title: Lack of neurotoxicity of the vascular targeting agent ZD6126 following repeated i.v. dosing in the rat.
abstract: The vascular targeting agent ZD6126 is a water-soluble prodrug of N-acetylcolchinol that acts by disrupting the cytoskeleton of tumor endothelial cells. It is currently undergoing clinical evaluation in man. As peripheral neuropathy is a major dose-limiting toxicity associated with tubulin binding agents, the neurotoxic potential of ZD6126 was investigated in male and female Wistar rats. ZD6126 was administered i.v. at up to maximum tolerated doses using subacute (0 to 20 mg/kg/d for 5 days) and chronic (0 to 10 mg/kg/d for 5 days, repeated monthly for 6 months) dosing regimens. A separate study examined a combination of ZD6126 (three cycles of ZD6126 given as in the chronic dosing regimen) and paclitaxel (12 mg/kg/wk for 9 weeks) to assess whether coadministration of ZD6126 altered the time course or magnitude of a paclitaxel-induced neuropathy. Neurotoxic potential was examined using a comprehensive series of tests including a functional observation battery, measurements of muscle strength (forelimb and hind limb grip strength), nociception (tail flick test), locomotor activity, neuropathology, and whole nerve electrophysiology. There was no evidence that ZD6126 induced neurotoxicity in the rat following either subacute or chronic i.v. dosing. In a chronic electrophysiology study, ZD6126 produced a slight slowing of the maturational increase of caudal nerve amplitude, with some evidence of reversibility. However, this was not associated with any changes in caudal nerve conduction velocity, motor nerve conduction velocity or amplitude, functional observation battery behavioral and function parameters (including no effects on tail flick latency), and neuropathology. As expected, paclitaxel administration was associated with a significant decrease in caudal nerve conduction velocity (P = 0.0001). Coadministration of ZD6126 did not increase the neurotoxicity of paclitaxel. These studies suggest that ZD6126 should not induce the peripheral neuropathy associated with other antitubulin chemotherapeutic agents and that ZD6126 may not exacerbate the neurotoxicity of other agents with dose-limiting neuropathies.
authors.affiliation: AstraZeneca UK Ltd., Safety Assessment UK, Macclesfield, Cheshire, United Kingdom. Steve.Horner@astrazeneca.com
authors.forename: Steve A
authors.initials: SA
authors.lastname: Horner
authors.forename: Sarah
authors.initials: S
authors.lastname: Gould
authors.forename: James P
authors.initials: JP
authors.lastname: Noakes
authors.forename: Niccola J
authors.initials: NJ
authors.lastname: Rattray
authors.forename: Sandra L
authors.initials: SL
authors.lastname: Allen
authors.forename: Elena
authors.initials: E
authors.lastname: Zotova
authors.forename: Joseph C
authors.initials: JC
authors.lastname: Arezzo
mesh_terms: D000818:Animals; D007275:Injections, Intravenous; D008297:Male; D009043:Motor Activity / Q000187:drug effects; D009417:Nerve Tissue / Q000187:drug effects / Q000473:pathology; D009422:Nervous System Diseases / Q000139:chemically induced* / Q000473:pathology; D009431:Neural Conduction / Q000187:drug effects; D009943:Organophosphorus Compounds / Q000008:administration & dosage / Q000633:toxicity*; D051381:Rats; D017208:Rats, Wistar
chemical_list: C455219:N-acetylcochinol-O-phosphate; D009943:Organophosphorus Compounds